Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice

H. Takakuwa, F. Goshima, N. Nozawa, Tetsushi Yoshikawa, H. Kimata, A. Nakao, A. Nawa, T. Kurata, T. Sata, Yukihiro Nishiyama

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The present study demonstrates that a clonal derivative (HF10) of HSV-1 strain HF effectively treated disseminated peritoneal neoplasm in an immunocompetent animal model and that all of survived mice acquired resistance to rechallenge with tumor cells. The survival time of mice treated with HF10 was longer than that of mice treated with hrR3, indicating that the oncolytic effect of HF10 was more potent than that of hrR3 in this animal model. HF10 induces syncytia formation in vitro, whereas hrR3 forms rounded CPE. The sequential administration of HF10 gave a long term survival of more than 90 days after tumor injection, with no signs of disease, in 8 of the 9 treated mice. The results suggest that treatment of disseminated peritoneal tumor with HF10 induces a specific antitumor immune response. Genomic structure determination showed that HF10 has a deletion of 3.9-kilobase pair (kbp) in the right end of UL and UL/IRL junction, resulting in the loss of UL 56 expression. A 2.3 kbp deletion and extensive rearrangement were also observed in the left end of the genome.

Original languageEnglish
Pages (from-to)813-825
Number of pages13
JournalArchives of Virology
Volume148
Issue number4
DOIs
Publication statusPublished - 01-04-2003
Externally publishedYes

Fingerprint

Human Herpesvirus 1
Peritoneal Neoplasms
Neoplasms
Animal Models
Giant Cells
Therapeutics
Genome
Injections

All Science Journal Classification (ASJC) codes

  • Virology

Cite this

Takakuwa, H. ; Goshima, F. ; Nozawa, N. ; Yoshikawa, Tetsushi ; Kimata, H. ; Nakao, A. ; Nawa, A. ; Kurata, T. ; Sata, T. ; Nishiyama, Yukihiro. / Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. In: Archives of Virology. 2003 ; Vol. 148, No. 4. pp. 813-825.
@article{de51271916ae4e7d89f8c471797046a1,
title = "Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice",
abstract = "The present study demonstrates that a clonal derivative (HF10) of HSV-1 strain HF effectively treated disseminated peritoneal neoplasm in an immunocompetent animal model and that all of survived mice acquired resistance to rechallenge with tumor cells. The survival time of mice treated with HF10 was longer than that of mice treated with hrR3, indicating that the oncolytic effect of HF10 was more potent than that of hrR3 in this animal model. HF10 induces syncytia formation in vitro, whereas hrR3 forms rounded CPE. The sequential administration of HF10 gave a long term survival of more than 90 days after tumor injection, with no signs of disease, in 8 of the 9 treated mice. The results suggest that treatment of disseminated peritoneal tumor with HF10 induces a specific antitumor immune response. Genomic structure determination showed that HF10 has a deletion of 3.9-kilobase pair (kbp) in the right end of UL and UL/IRL junction, resulting in the loss of UL 56 expression. A 2.3 kbp deletion and extensive rearrangement were also observed in the left end of the genome.",
author = "H. Takakuwa and F. Goshima and N. Nozawa and Tetsushi Yoshikawa and H. Kimata and A. Nakao and A. Nawa and T. Kurata and T. Sata and Yukihiro Nishiyama",
year = "2003",
month = "4",
day = "1",
doi = "10.1007/s00705-002-0944-x",
language = "English",
volume = "148",
pages = "813--825",
journal = "Archives of Virology",
issn = "0304-8608",
publisher = "Springer Wien",
number = "4",

}

Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. / Takakuwa, H.; Goshima, F.; Nozawa, N.; Yoshikawa, Tetsushi; Kimata, H.; Nakao, A.; Nawa, A.; Kurata, T.; Sata, T.; Nishiyama, Yukihiro.

In: Archives of Virology, Vol. 148, No. 4, 01.04.2003, p. 813-825.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice

AU - Takakuwa, H.

AU - Goshima, F.

AU - Nozawa, N.

AU - Yoshikawa, Tetsushi

AU - Kimata, H.

AU - Nakao, A.

AU - Nawa, A.

AU - Kurata, T.

AU - Sata, T.

AU - Nishiyama, Yukihiro

PY - 2003/4/1

Y1 - 2003/4/1

N2 - The present study demonstrates that a clonal derivative (HF10) of HSV-1 strain HF effectively treated disseminated peritoneal neoplasm in an immunocompetent animal model and that all of survived mice acquired resistance to rechallenge with tumor cells. The survival time of mice treated with HF10 was longer than that of mice treated with hrR3, indicating that the oncolytic effect of HF10 was more potent than that of hrR3 in this animal model. HF10 induces syncytia formation in vitro, whereas hrR3 forms rounded CPE. The sequential administration of HF10 gave a long term survival of more than 90 days after tumor injection, with no signs of disease, in 8 of the 9 treated mice. The results suggest that treatment of disseminated peritoneal tumor with HF10 induces a specific antitumor immune response. Genomic structure determination showed that HF10 has a deletion of 3.9-kilobase pair (kbp) in the right end of UL and UL/IRL junction, resulting in the loss of UL 56 expression. A 2.3 kbp deletion and extensive rearrangement were also observed in the left end of the genome.

AB - The present study demonstrates that a clonal derivative (HF10) of HSV-1 strain HF effectively treated disseminated peritoneal neoplasm in an immunocompetent animal model and that all of survived mice acquired resistance to rechallenge with tumor cells. The survival time of mice treated with HF10 was longer than that of mice treated with hrR3, indicating that the oncolytic effect of HF10 was more potent than that of hrR3 in this animal model. HF10 induces syncytia formation in vitro, whereas hrR3 forms rounded CPE. The sequential administration of HF10 gave a long term survival of more than 90 days after tumor injection, with no signs of disease, in 8 of the 9 treated mice. The results suggest that treatment of disseminated peritoneal tumor with HF10 induces a specific antitumor immune response. Genomic structure determination showed that HF10 has a deletion of 3.9-kilobase pair (kbp) in the right end of UL and UL/IRL junction, resulting in the loss of UL 56 expression. A 2.3 kbp deletion and extensive rearrangement were also observed in the left end of the genome.

UR - http://www.scopus.com/inward/record.url?scp=0037388153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037388153&partnerID=8YFLogxK

U2 - 10.1007/s00705-002-0944-x

DO - 10.1007/s00705-002-0944-x

M3 - Article

VL - 148

SP - 813

EP - 825

JO - Archives of Virology

JF - Archives of Virology

SN - 0304-8608

IS - 4

ER -